日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors

c-JUN增强CRISPR敲入抗B7-H3 CAR T细胞在小细胞肺癌和胸腔SMARCA4缺陷型未分化肿瘤中的功能

Hyatt Balke-Want,Vimal Keerthi,Maria Del Carmen Arenas,Yiyun Chen,Meena Malipatlolla,Dorota D Klysz,Peng Xu,Katie Ho,Kyle Asano,David Stahl,Jing Huang,Aidan Retherford,Sunny Patel,Carley Fowler,Lukas Maas,Nikolaos Gkitsas-Long,Qiaoshi Jiang,Xikun Liu,Roland Ullrich,Julie George,Sabine Heitzeneder,Ramya Tunuguntla,Julien Sage,Elena Sotillo,Crystal L Mackall,Steven A Feldman

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

Zamtocabtagene autoleucel 治疗复发/难治性 B 细胞非霍奇金淋巴瘤:一项 CD20/19 串联 CAR T 细胞 I 期试验的 5 年随访结果

Balke-Want, Hyatt; Gödel, Philipp; Schmid, Christoph; Ayuk, Francis; Friedrichs, Birte; van Heteren, Pearl; Holtkamp, Silke; Zadoyan, Gregor; Brillant, Corinne; Costa, Joana; Hanssens, Linda; Holzer, Tatjana; Wöhle, Christian; Biedermann, Stefanie; Bürger, Iris; Orentas, Rimas; Overstijns, Toon; Scheid, Christoph; Holtick, Udo; Miltenyi, Stefan; Hallek, Michael; Borchmann, Peter; Kutsch, Nadine

Engineering T cell therapies for lung cancer

针对肺癌的T细胞疗法工程

Balke-Want, Hyatt; Keerthi, Vimal; Feldman, Steven A

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

难治性多发性骨髓瘤的序贯BCMA CAR T细胞疗法

Richardson, Tim; Holtick, Udo; Frenking, Jan-Hendrik; Tharmaseelan, Hishan; Balke-Want, Hyatt; Flümann, Ruth; Mai, Elias Karl; Sauer, Sandra; Teipel, Raphael; von Bonin, Malte; Hallek, Michael; Scheid, Christof; Gödel, Philipp

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

抗CD19/CTLA-4转换可提高靶向CD80/86上调的弥漫性大B细胞淋巴瘤(DLBCL)的CAR T细胞的疗效和选择性。

Lars Fabian Prinz ,Tobias Riet ,Daniel Felix Neureuther ,Simon Lennartz ,Danuta Chrobok ,Hanna Hübbe ,Gregor Uhl ,Nicole Riet ,Petra Hofmann ,Marianna Hösel ,Adrian Georg Simon ,Luis Tetenborg ,Paul Segbers ,Joji Shimono ,Philipp Gödel ,Hyatt Balke-Want ,Ruth Flümann ,Gero Knittel ,Hans Christian Reinhardt ,Christoph Scheid ,Reinhard Büttner ,Björn Chapuy ,Roland Tillmann Ullrich ,Michael Hallek ,Markus Martin Chmielewski

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

同源性独立的靶向插入 (HITI) 可实现引导 CAR 敲入和高效的临床规模 CAR-T 细胞制造

Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G Mancini, Gavin L Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J Fisher, Annie K Brown, Ramya H Tunuguntla, Shabnum Patel, Elena Sotillo, Crystal L Mackall, Steven A Feldman

Non-viral chimeric antigen receptor (CAR) T cells going viral

非病毒嵌合抗原受体 (CAR) T 细胞病毒化

H Balke-Want, V Keerthi, A Cadinanos-Garai, C Fowler, N Gkitsas, A K Brown, R Tunuguntla, M Abou-El-Enein, S A Feldman

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT

P1184:MB-CART2019.1治疗复发或难治性B细胞非霍奇金淋巴瘤患者的I期临床试验:2年随访报告

Lugnier, C; Birkner, T; Sommerlatte, S; Hense, H; Kraeft, A-L; Christmann, J; Foerster, S; Schoffer, O; Stein, A; Reichelt, R; Knauf, W; C. Biermann; Overheu, O; Tannapfel, A; Schildmann, J; Reinacher-Schick, A; Schmitt, J; Borchmann, P; Lohneis, A; Gödel, P; Balke-Want, H; Schmid, C; Ayuk, F; Holtkamp, S; Hanssens, L; Zadoyan, G; Friedrichs, B; Assenmacher, M; Bürger, I; Schneider, D; Overstijns, T; Scheid, C; Holtick, U; Miltenyi, S; Hallek, M

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

在转录、遗传和药物反应水平上解剖淋巴结 B 细胞淋巴瘤的肿瘤内异质性

Tobias Roider, Julian Seufert, Alexey Uvarovskii, Felix Frauhammer, Marie Bordas, Nima Abedpour, Marta Stolarczyk, Jan-Philipp Mallm, Sophie A Herbst, Peter-Martin Bruch, Hyatt Balke-Want, Michael Hundemer, Karsten Rippe, Benjamin Goeppert, Martina Seiffert, Benedikt Brors, Gunhild Mechtersheimer, T

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

系统性激酶抑制剂谱分析发现 CDK9 是 NUT 中线癌的合成致死靶点

Brägelmann, Johannes; Dammert, Marcel A; Dietlein, Felix; Heuckmann, Johannes M; Choidas, Axel; Böhm, Stefanie; Richters, André; Basu, Debjit; Tischler, Verena; Lorenz, Carina; Habenberger, Peter; Fang, Zhizhou; Ortiz-Cuaran, Sandra; Leenders, Frauke; Eickhoff, Jan; Koch, Uwe; Getlik, Matthäus; Termathe, Martin; Sallouh, Muhammad; Greff, Zoltán; Varga, Zoltán; Balke-Want, Hyatt; French, Christopher A; Peifer, Martin; Reinhardt, H Christian; Örfi, László; Kéri, György; Ansén, Sascha; Heukamp, Lukas C; Büttner, Reinhard; Rauh, Daniel; Klebl, Bert M; Thomas, Roman K; Sos, Martin L